Korean biopharma Samsung Bioepis has announced the launch of OPUVIZ 40 mg/mL solution for injection in a vial, a biosimilar referencing Eylea (aflibercept), across Europe, starting today.
The biosimilar, available in pre-filled syringes, obtained a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in November 2025.
In its statement, Samsung Bioepis said the medicine is expected to be available in the market in the third quarter of this year.
This is the fifth biosimilar product commercialised by the firm, which has already launched BYOOVIZ (ranibizumab) and XBRYK (denosumab) in Europe earlier this year.
"We are pleased to launch OPUVIZ in Europe, marking a significant milestone in expanding patient access to ophthalmology treatments," said Antonio Rito, Vice President and Head of Europe, at Samsung Bioepis.
Leveraging our direct commercialisation capabilities, we will work closely with healthcare professionals and payers to facilitate access to this important medicine, so that patients can benefit from quality-assured, safe and effective biosimilar alternatives.
In January of this year, Samsung Bioepis announced that it had signed a settlement and licence agreement with Regeneron and Bayer regarding the commercialisation of its biosimilar to Eylea 2 mg (aflibercept 40 mg/mL solution) in Europe and the Rest of the World (RoW).
It added that its aflibercept biosimilar is also available in the Republic of Korea under the brand name AFILIVU.